Literature DB >> 10933365

Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients.

G E Cooke1, G M Eaton, G Whitby, R A Kennedy, P F Binkley, M L Moeschberger, C V Leier.   

Abstract

OBJECTIVES: We hypothesized that plasma factors important for the development of atherosclerosis play a major role in the occurrence of cardiac allograft vasculopathy (CAV).
BACKGROUND: Cardiac allograft vasculopathy is a major cause of death among heart transplant recipients, has a poorly understood pathogenesis and has similarities to atherosclerotic coronary disease.
METHODS: The study population consisted of 93 postcardiac transplant recipients. Thirty-one patients with congestive heart failure (CHF) and 18 healthy individuals served as control subjects. Posttransplant coronary anatomy was evaluated by angiography and intravascular ultrasound. Laboratory analyses of lipids, homocysteine, vitamin B12 and folate, fibrinogen, von Willebrand factor antigen (vWFAg) and renin were obtained on all participants.
RESULTS: Posttransplant patients were found to have elevated serum triglycerides, total cholesterol/ high-density lipoprotein cholesterol ratio, lipoprotein (a), homocysteine, vWFAg, fibrinogen and renin and lower high-density lipoprotein cholesterol. Most of these laboratory atherogenic factors were also elevated to a similar degree in the CHF control population. Although most atherogenic markers were elevated, there was little correlation with CAV severity. Cardiac allograft vasculopathy severity varied with time after transplantation, 3-hydroxy-methyl-glutaryl-coenzyme A reductase inhibitor use and prior cytomegalovirus infection. Even within the normal range, lower RBC folate levels were associated with increased severity of CAV.
CONCLUSIONS: The posttransplant course is associated with increased clinical and laboratory atherogenic factors, some of which likely contribute to the severity of coronary vasculopathy. Compared with normal control subjects, many of these markers are already increased in pretransplant CHF patients with or without occlusive coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933365     DOI: 10.1016/s0735-1097(00)00756-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  Clinical characteristics, morbidity, and prognostic value of concomitant coronary artery disease in idiopathic dilated cardiomyopathy.

Authors:  Lutz Frankenstein; Henrik Hees; Tobias Taeger; Hanna Froehlich; Andreas Dösch; Rita Cebola; Christian Zugck; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2013-06-26       Impact factor: 5.460

Review 2.  Coronary artery vasculopathy in pediatric cardiac transplant patients: the therapeutic potential of immunomodulators.

Authors:  Biagio Pietra; Mark Boucek
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

3.  Risk factors of cardiac allograft vasculopathy.

Authors:  Bożena Szyguła-Jurkiewicz; Wioletta Szczurek; Mariusz Gąsior; Marian Zembala
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-12-30

4.  Lipoprotein(a) is associated with left ventricular systolic dysfunction in a Chinese population of patients with hypertension and without coronary artery disease.

Authors:  Yong Wang; Heng Ma; Jun Yang; Qiujing Chen; Lin Lu; Ruiyan Zhang
Journal:  Arch Med Sci       Date:  2016-05-12       Impact factor: 3.318

5.  Nonlinear association between blood lead and hyperhomocysteinemia among adults in the United States.

Authors:  Minghui Li; Lihua Hu; Wei Zhou; Tao Wang; Lingjuan Zhu; Zhenyu Zhai; Huihui Bao; Xiaoshu Cheng
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.